glp-1 sglt2 SGLTi and in HF SGLT-2 inhibitors and GLP-1 receptor

Its rooted in real neurological changes that come with perimenopause and midlife

Eder, L., Thavaneswaran, A., Chandran, V., Cook, R

However, in a sensitivity analysis of the REWIND study with dulaglutide, the relative risk reduction for a 40% or 50% decrease in eGFR was 30% and 44%, both significant, in the dulaglutide group compared to placebo, respectively.92 This lower risk of developing macroalbuminuria was also confirmed in an exploratory analysis of the ELIXA (lixisenatide) study.93 In the EXSCEL study (exenatide LAR), renal episodes were analyzed as additional microvascular episodes, and no differences were observed in the risk of episodes related to decreased eGFR, but differences were observed in the composite episode, which included decreased eGFR and macroalbuminuria, although only after adjustment94 (Table 2)

We must continue to explore these links